On March 29th, three sets of leadless cardiac pacemakers, benefiting from the "Hong Kong-Macao medical connect" policy, completed import customs procedures and will soon be transported to the Sun Yat-sen Memorial Hospital of Sun Yat-sen University for clinical use. This marks the first batch of cardiac pacemakers imported through the "Hong Kong-Macao medical connect" nationwide, providing mainland patients with more diverse options and convenient access to cardiac pacemakers.

The "Hong Kong-Macao medical connect" policy, authorized by the State Council, allows clinically urgent drugs that have not yet been marketed in the mainland but are available in Hong Kong and Macao, as well as advanced medical devices that have been procured and used in public hospitals in Hong Kong and Macao, and feature cutting-edge clinical technologies, to be used in qualified medical institutions in the mainland cities in the Guangdong-Hong Kong-Macao Greater Bay Area after approval by the People's Government of Guangdong Province.

Since the implementation of the policy, six batches of clinically urgent imported drugs and medical devices from Hong Kong and Macao have been released, covering 19 designated medical institutions in cities such as Guangzhou, Shenzhen, and Zhongshan. According to statistics, Guangzhou Customs has supervised the import of over 40 batches of clinically urgent medical devices from Hong Kong and Macao, with a total value exceeding 22.3 million yuan since the beginning of this year, representing an increase of 1.8 times and 8.3 times respectively compared to the same period last year.

"In recent years, the demand for cardiac pacemakers among mainland patients has been increasing, and Guangzhou has become the city with the highest number of cardiac pacemaker implantation surgeries in South China," said Huo Peiqiong, General Manager of CR Pharmaceutical (Guangdong). "The leadless cardiac pacemaker introduced through the 'Hong Kong-Macao medical connect' has advantages such as small size and fewer complications, which can better improve patient experience and enhance the quality of life after surgery." She added, "It is estimated that around 30 to 50 sets of cardiac pacemakers will be imported through the Guangzhou Customs throughout this year."

Source: Yangcheng Evening News

全国首批“港澳药械通”进口心脏起搏器在广州顺利通关

3月29日，3套享受“港澳药械通”政策的无导线心脏起搏器顺利办结进口通关手续，不久后将运往中山大学孙逸仙纪念医院投入临床使用。这是全国首批通过“港澳药械通”进口的心脏起搏器，将为内地患者获得心脏起搏器提供更多样选择和更便利途径。

据悉，“港澳药械通”政策是经国务院授权，允许临床急需、还未在内地上市但已在港澳上市的药品，以及临床急需、港澳公立医院已采购使用、具有临床应用先进性的医疗器械，经广东省人民政府批准后，在粤港澳大湾区内地符合条件的医疗机构使用的一项政策。

“港澳药械通”政策实施以来，已发布6批粤港澳大湾区内地临床急需进口港澳药品和医疗器械目录，覆盖广州、深圳、中山等地市的19家指定医疗机构。据统计，今年以来，广州海关已累计监管进口临床急需港澳药械超40批次，货值超2230万元，同比分别增长1.8倍和8.3倍。

“近年来，内地患者对于心脏起搏器的需求越来越大，广州已成为华南地区心脏起搏器植入手术最多的城市。此次通过‘港澳药械通’引入的这款无导线心脏起搏器具有体积小、并发症更少等优点，能更好改善患者的体验，提高患者术后的生活质量。”华润广东医药有限公司总经理霍佩琼介绍，“预计今年全年将通过‘港澳药械通’从广州通关进口30套到50套左右的心脏起搏器。”

文、图丨记者 汪海晏 通讯员 关悦
翻译丨刘佳慧